Inocucor Expands Canada Sales and Distribution Reach

Thursday, August 31, 2017

Montreal agri-tech company appoints V.P. of Canadian Sales, adds Ontario sales leader

Continue Reading

Mighty Oak Medical and OrthoPediatrics Team Up to Bring Pediatric-Friendly Spinal Navigation to Children’s Hospitals

Tuesday, August 29, 2017

Mighty Oak Medical and OrthoPediatrics recently announced a navigation partnership that can provide unsurpassed screw placement accuracy in the pediatric population. 
Continue Reading

Boettcher Foundation Helps Early-Career Scientists

Tuesday, August 29, 2017


Colorado BioScience Association, Senator Michael Bennet Host U.S. Food and Drug Administration Commissioner, Dr. Scott Gottlieb, for Life Science Industry Roundtable

Tuesday, August 22, 2017

Colorado life science leaders cover the regulatory landscape for diagnostics, FDA’s approach to bioscience and technology and the 21st Century Cures Act – progress and future outlook 
Continue Reading

RxREVU Modernizes Prescription Management

Tuesday, August 22, 2017


Neuraptive Therapeutics, Inc. raised 1 million in a seed funding round

Monday, August 21, 2017


MBC Pharma Inc. Awarded a SBIR Phase I Grant to Investigate Novel Compounds Against Osteomyelitis

Friday, August 18, 2017

MBC Pharma Inc., a privately held biopharmaceutical company announced today, that it has been awarded an $594,202 Phase I Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health. MBC will use this 2-year grant to expand their discovery pipeline to include bone-targeted antibiotics for the treatment of osteomyelitis and other bone infections. The work will focus on the synthesis and efficacy testing of novel bone-targeted conjugates of agents with known anti-infective activities. 

Precision Medicine in 3D

Tuesday, August 15, 2017

Continue Reading

2017 Rocky Mountain Life Science Investor and Partnering Conference Announces Presenting Companies

Monday, August 14, 2017

Continue Reading

Arca Biopharma Announces Genetic-AF Data and Safety Monitoring Board Recommendation To Complete Phase 2B Genetic-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2b Interim Analysis

Thursday, August 10, 2017